Bio Insight Bio Feature
Every December, generic and biosimilar teams across Asia Pacific sit down to fix their launch calendars for the coming year. The regulatory side of that ex...
November 19, 2026 | Analysis
On 13 November, 16 new medicines joined Japan's National Health Insurance (NHI) price list. It was the last of the seven listing rounds Japan now runs each...
November 18, 2026 | Analysis
For most of the last two decades, a year in drug approvals could be summarised in a single number: how many new molecular entities the US Food and Drug Adm...
November 17, 2026 | Analysis
The record, counted to 14 November 2026. Method What counts An FDA Breakthrough Therapy designation disclosed by the sponsor or a licensee i...
November 16, 2026 | Analysis
As cell and gene therapies advance across Asia-Pacific, supply chains must connect complex manufacturing processes with individual patients’ treatmen...
November 12, 2026 | Expert Insight
This analysis comes from the distributor's side of that transaction. BulkGLP is a US supplier of research peptides that publishes its lot reports online. B...
November 11, 2026 | Analysis
Every November, the same ritual plays out in a European convention hall. University technology-transfer offices arrive with slides counting patents filed, ...
November 11, 2026 | Analysis
Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...
November 05, 2026 | Analysis
Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...
November 03, 2026 | Regulatory
Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...
November 02, 2026 | Analysis
Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...
October 29, 2026 | Analysis
Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...
October 28, 2026 | Analysis
Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...
October 27, 2026 | Analysis
Walk into the finished goods area of almost any medical device plant at the end of a quarter and you will find the same quiet scene. Pallets of product sit...
October 22, 2026 | Analysis
Most Read
Bio Jobs
News